NEW YORK (GenomeWeb News) – Cambridge Isotope Laboratories today announced an exclusive worldwide commercial supply agreement with Nexomics Biosciences.
Under the terms of the deal, Nexomics is providing protein production services, and CIL is providing global sales and marketing support. Financial and other terms were not disclosed.
Headquartered in North Brunswick, NJ, Nexomics is a structural biology and protein production CRO.
"The capabilities that Nexomics offers, such as the production and NMR analysis of isotope-enriched protein, will enhance and expand CIL's current product offering," CIL CEO Joel Bradley said in a statement.